Differential Expression of MiRNAs in Papillary Thyroid Carcinoma Compared to Multinodular Goiter Using Formalin Fixed Paraffin Embedded Tissues

Overview

Journal Endocr Pathol

Specialties Endocrinology
Pathology

Date 2007 Dec 7

PMID 18058265

Citations 101

Authors

Michael T Tetzlaff

Aihua Liu

Xiaowei Xu

Stephen R Master

Don A Baldwin

John W Tobias

Virginia A LiVolsi

Zubair W Baloch

Affiliations

Soon will be listed here.

Abstract

microRNAs (miRNAs) are approximately 22 nt RNAs that negatively regulate target gene expression. Their dysregulation has been implicated in the pathogenesis of a number of human cancers, including papillary thyroid carcinoma (PTC). Whereas previous studies using microarray technologies have largely relied on the ability to procure fresh tissue at the time of surgery to characterize miRNA signatures in PTC, we exploited the ability to procure sufficient miRNA from formalin-fixed paraffin-embedded (FFPE) tissue to describe a series of miRNAs whose expression is dysregulated in PTC compared to benign proliferative multinodular goiter (MNG). We identified 13 miRNAs upregulated and 26 miRNAs downregulated in PTC versus MNG. These include miRNA-21, miRNA-31, miRNA-221, and miRNA-222. Their dysregulation was further validated by real time RT-PCR analysis in an independent set of FFPE tissues. Many of these have previously been described in fresh tissue studies as altered in PTC, confirming the utility of this approach. These results further highlight the applicability of miRNA expression patterns as potential markers of human cancer, and our results suggest that FFPE tissues are suitable resources for such miRNA expression analyses. The ability to utilize FFPE tissue in the molecular characterization of human malignancy will unlock a rich resource for future cancer studies.

Citing Articles

The Implications for Clinical Practice of Circulating miR144-3p and miR190a-5p as Promising Diagnostic Biomarkers for Thyroid Nodule Differentiation.

Hassan B, Omran M, Youssef M, Refaat M, Abouzid A, Abdel Wahab A Technol Cancer Res Treat. 2024; 23:15330338241291637.

PMID: 39703128 PMC: 11662322. DOI: 10.1177/15330338241291637.

Research on the expression of Mir-218-2 in the serum of patients with papillary thyroid cancer and its clinical significance.

He H, Hao D, Tian L, Zhu C, Guo L, Zhang K Eur J Transl Myol. 2024; 34(3).

PMID: 39221591 PMC: 11487670. DOI: 10.4081/ejtm.2024.12678.

Trials and Tribulations of MicroRNA Therapeutics.

Seyhan A Int J Mol Sci. 2024; 25(3).

PMID: 38338746 PMC: 10855871. DOI: 10.3390/ijms25031469.

MiR-20b Tissue Expression Level Displays the Diagnostic Value in Papillary Thyroid Carcinoma.

Honardoost M, Maghsoomi Z, Karimi Behnagh A, Nazanin Hosseinkhan , Abdolmaleki F, Panahi M Med J Islam Repub Iran. 2023; 37:101.

PMID: 38021380 PMC: 10657271. DOI: 10.47176/mjiri.37.101.

New biomarkers: prospect for diagnosis and monitoring of thyroid disease.

Macvanin M, Gluvic Z, Zaric B, Essack M, Gao X, Isenovic E Front Endocrinol (Lausanne). 2023; 14:1218320.

PMID: 37547301 PMC: 10401601. DOI: 10.3389/fendo.2023.1218320.

References

He H, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S . The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci U S A. 2005; 102(52):19075-80. PMC: 1323209. DOI: 10.1073/pnas.0509603102. View

Cinti R, Yin L, Ilc K, Berger N, Basolo F, Cuccato S . RET rearrangements in papillary thyroid carcinomas and adenomas detected by interphase FISH. Cytogenet Cell Genet. 2000; 88(1-2):56-61. DOI: 10.1159/000015485. View

Ciafre S, Galardi S, Mangiola A, Ferracin M, Liu C, Sabatino G . Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun. 2005; 334(4):1351-8. DOI: 10.1016/j.bbrc.2005.07.030. View

Volinia S, Calin G, Liu C, Ambs S, Cimmino A, Petrocca F . A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006; 103(7):2257-61. PMC: 1413718. DOI: 10.1073/pnas.0510565103. View

Fukushima T, Suzuki S, Mashiko M, Ohtake T, Endo Y, Takebayashi Y . BRAF mutations in papillary carcinomas of the thyroid. Oncogene. 2003; 22(41):6455-7. DOI: 10.1038/sj.onc.1206739. View

Pierotti M, Santoro M, Jenkins R, Sozzi G, Bongarzone I, Grieco M . Characterization of an inversion on the long arm of chromosome 10 juxtaposing D10S170 and RET and creating the oncogenic sequence RET/PTC. Proc Natl Acad Sci U S A. 1992; 89(5):1616-20. PMC: 48503. DOI: 10.1073/pnas.89.5.1616. View

Kutay H, Bai S, Datta J, Motiwala T, Pogribny I, Frankel W . Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J Cell Biochem. 2006; 99(3):671-8. PMC: 3033198. DOI: 10.1002/jcb.20982. View

Chan J, Krichevsky A, Kosik K . MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res. 2005; 65(14):6029-33. DOI: 10.1158/0008-5472.CAN-05-0137. View

Namba H, Rubin S, Fagin J . Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. Mol Endocrinol. 1990; 4(10):1474-9. DOI: 10.1210/mend-4-10-1474. View

10.

Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B . BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst. 2003; 95(8):625-7. DOI: 10.1093/jnci/95.8.625. View

11.

Nikiforova M, Kimura E, Gandhi M, Biddinger P, Knauf J, Basolo F . BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab. 2003; 88(11):5399-404. DOI: 10.1210/jc.2003-030838. View

12.

Iorio M, Ferracin M, Liu C, Veronese A, Spizzo R, Sabbioni S . MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005; 65(16):7065-70. DOI: 10.1158/0008-5472.CAN-05-1783. View

13.

Esapa C, Johnson S, Kendall-Taylor P, Lennard T, Harris P . Prevalence of Ras mutations in thyroid neoplasia. Clin Endocrinol (Oxf). 1999; 50(4):529-35. DOI: 10.1046/j.1365-2265.1999.00704.x. View

14.

Nelson P, Baldwin D, Marie Scearce L, Oberholtzer J, Tobias J, Mourelatos Z . Microarray-based, high-throughput gene expression profiling of microRNAs. Nat Methods. 2005; 1(2):155-61. DOI: 10.1038/nmeth717. View

15.

Suarez H . Genetic alterations in human epithelial thyroid tumours. Clin Endocrinol (Oxf). 1998; 48(5):531-46. DOI: 10.1046/j.1365-2265.1998.00443.x. View

16.

Nelson P, Baldwin D, Kloosterman W, Kauppinen S, Plasterk R, Mourelatos Z . RAKE and LNA-ISH reveal microRNA expression and localization in archival human brain. RNA. 2005; 12(2):187-91. PMC: 1370897. DOI: 10.1261/rna.2258506. View

17.

Baloch Z, LiVolsi V . Fine-needle aspiration of thyroid nodules: past, present, and future. Endocr Pract. 2004; 10(3):234-41. DOI: 10.4158/EP.10.3.234. View

18.

Calin G, Liu C, Sevignani C, Ferracin M, Felli N, Dumitru C . MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A. 2004; 101(32):11755-60. PMC: 511048. DOI: 10.1073/pnas.0404432101. View

19.

Kroll T, Sarraf P, Pecciarini L, Chen C, Mueller E, Spiegelman B . PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. Science. 2000; 289(5483):1357-60. DOI: 10.1126/science.289.5483.1357. View

20.

Tallini G, Santoro M, Helie M, Carlomagno F, Salvatore G, Chiappetta G . RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clin Cancer Res. 1998; 4(2):287-94. View